2021

25/11/2021

AGM Presentation 2021

24/11/2021

FDA advises regulatory pathway for PromarkerD in US

23/11/2021

Proteomics enters lucrative UK market for kidney test – The West Australian

23/11/2021

PromarkerD distribution network expands to Britain – Yahoo! Finance

23/11/2021

PromarkerD distribution network expands to Britain

16/11/2021

New Directors appointed to Company Board

05/11/2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline – Market Watch

05/11/2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

03/11/2021

Proteomics (ASX:PIQ) awarded $100,000 project grant – The Market Herald

03/11/2021

Proteomics International awarded $100,000 manufacturing funding

30/10/2021

October Newsletter 2021

27/10/2021

PromarkerD at ASN Kidney Week

18/10/2021

Clinical study boosts Proteomics kidney test – The West Australian

18/10/2021

PromarkerD at AMCP Nexus

17/09/2021

PromarkerD at EASD

12/08/2021

Proteomics International Laboratories (ASX:PIQ) contracts Biotem to manufacture test kits – The Market Herald

12/08/2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

11/08/2021

Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress

10/08/2021

Endometriosis Blood Test – ABC Radio

05/08/2021

Proteomics International to collaborate with University of Melbourne and Royal Women’s Hospital to develop a test for endometriosis – Proactive Investors

04/08/2021

Proteomics International to collaborate on world first blood test for endometriosis – The Sentiment

04/08/2021

Proteomics to collaborate to validate test for endometriosis

31/07/2021

July Newsletter 2021

23/07/2021

6PR (Audio) – Proteomics: Predicting a disease before you get it – now that’s novel

22/07/2021

Proteomics International engages Abcam to manufacture PromarkerD reagents – Proactive Investors

22/07/2021

Proteomics engages Abcam to manufacture PromarkerD reagents

20/07/2021

Investor Presentation – Non-deal Roadshow

16/07/2021

Proteomics International Laboratories (ASX:PIQ) shows diabetes drug improves PromarkerD risk scores – The Market Herald

16/07/2021

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

12/07/2021

PromarkerD at the Australasian Diabetes Congress

28/06/2021

Vast US market opportunity seen for Proteomics kidney test – The West Australian

28/06/2021

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

23/06/2021

PromarkerD at the American Diabetes Association’s 81st Scientific Sessions

10/06/2021

CCO and CFO appointed to bolster executive team

02/06/2021

PromarkerD at ERA-EDTA

19/05/2021

Proteomics nails Avance testing contract – The West Australian

18/05/2021

Proteomics secures major analytical services contract

14/05/2021

PromarkerD at Virtual ISPOR

13/05/2021

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

30/04/2021

April Newsletter 2021

29/04/2021

Proteomics International files US FDA 513(g) regulatory submission

23/04/2021

Proteomics International achieves ISO 13485 certification

19/03/2021

PromarkerD at AMCP Virtual

09/03/2021

Investor Presentation – Euroz Hartleys Institutional Conference

24/02/2021

PromarkerD at EDEC 2021

10/02/2021

PromarkerD: Predicting Diabetic Kidney Disease Before Symptoms Arrive – Medical Forum Magazine

09/02/2021

Proteomics International (ASX:PIQ) pursues FDA approval for PromarkerD – The Market Herald

09/02/2021

Proteomics seeks FDA approval for blood test kit – The West Australian

08/02/2021

Proteomics International seeks FDA approval for PromarkerD

31/01/2021

January Newsletter 2021

27/01/2021

Proteomics International at Lorne Proteomics 2021

Subscribe
  • This field is for validation purposes and should be left unchanged.